CDKN1B and glioblastoma: Using a genetic approach in glioblastoma, miR-221/222 was demonstrated to downregulate the cell cycle inhibitors/tumor suppressors CDKN1B (p27 gene) and CDKN1C (p57 gene), resulting in enhanced cell proliferation.